Business Context and Reporting Period
Autonomix Medical, Inc. (AMIX) filed a Form 8-K on July 10, 2024, reporting the entry into a material definitive agreement. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The transaction involves the issuance of equity rather than cash consideration.
- Equity Issuance: 250,000 shares of common stock issued to RF Innovations, Inc. (RFI).
- Consideration: Perpetual, non-exclusive, worldwide, royalty-free, fully paid license for RFI's Apex 6 Radiofrequency Generator technology.
Material Changes
The primary material change is the acquisition of intellectual property rights via a license agreement with RFI. The transaction is expected to close before the end of July 2024. The license excludes the right to sell certain products for the treatment of spine pain.
Outlook, Risks, and Unusual Items
Management Commentary: The Company issued a press release on July 15, 2024, regarding this transaction. The Apex 6 Generator is an FDA-cleared ablation technology for pain management in the peripheral nervous system.
Risks and Contingencies:
- Termination Rights: RFI may terminate the license if the Company breaches representations, warranties, or covenants, or if the Company faces bankruptcy or insolvency.
- Unregistered Securities: The shares issued to RFI were sold pursuant to Section 4(a)(2) of the Securities Act and/or Regulation D and were not registered.
- Forward-Looking Statements: Representations and warranties in the agreement are for risk allocation between parties and may not reflect materiality standards for investors.
Investor Verification Checklist
- Verify the closing date of the transaction (expected before end of July 2024).
- Review the full text of the License Agreement (Exhibit 10.1) for specific restrictions on the spine pain treatment exclusion.
- Confirm the impact of the 250,000 share issuance on total outstanding shares and potential dilution.
- Monitor future filings for any updates on the commercialization of the Licensed Products.